1. Home
  2. BRCB vs BNR Comparison

BRCB vs BNR Comparison

Compare BRCB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRCB

Black Rock Coffee Bar Inc.

N/A

Current Price

$12.26

Market Cap

261.8M

Sector

N/A

ML Signal

N/A

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.00

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRCB
BNR
Founded
2008
2014
Country
United States
China
Employees
2800
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.8M
252.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BRCB
BNR
Price
$12.26
$16.00
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$26.83
N/A
AVG Volume (30 Days)
615.2K
26.3K
Earning Date
03-03-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.77
$111.65
Revenue Next Year
$24.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.51
$2.18
52 Week High
$30.40
$41.72

Technical Indicators

Market Signals
Indicator
BRCB
BNR
Relative Strength Index (RSI) 31.47 35.27
Support Level $11.51 $15.52
Resistance Level $17.60 $24.23
Average True Range (ATR) 1.10 1.77
MACD -0.39 -0.03
Stochastic Oscillator 5.46 10.78

Price Performance

Historical Comparison
BRCB
BNR

About BRCB Black Rock Coffee Bar Inc.

Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: